Complete disruption of gD binding to HVEM alters virus replication and host receptor homeostasis Authors: Deepak Arya, Kati Tormanen, Jay J. Oh, Shaohui Wang, Homayon Ghiasi, Robert Kalejta, Clinton Jones, Robert Kalejta, Clinton Jones, Robert Kalejta, Clinton Jones, Robert Kalejta, Clinton Jones Published: 2026 ABSTRACT Herpes simplex virus 1 (HSV‑1) establishes infection through coordinated interactions of multiple viral glycoproteins with host cell receptors. Interactions between the viral glycoprotein D (gD) and the immunomodulatory cellular receptor HVEM (herpesvirus entry mediator) critically influence HSV‑1 latency and reactivation by regulating both receptor engagement and immunomodulatory signaling in the corneal epithelium, immune cells, and neurons. The underlying mechanisms of these phenotypes remain poorly understood because no tools selectively block their interaction. To dissect the contributions of individual amino acids (aa) to HVEM binding, we co‑immunoprecipitated wild‑type (WT) and mutant (Q27P and Q27A‑L28A‑T29A) forms of gD that disrupt gD binding to HVEM. We found that gD aa Q27-T29 were critical for HVEM binding, with the triple mutant showing greater disruption of HVEM binding than the Q27P single mutation, as assessed by co-immunoprecipitation and immunostaining. To map gD binding to HVEM and assess functional relevance, we constructed two recombinant viruses: a single-amino-acid (aa) gD mutation (v27 virus) and a triple-aa mutation in gD (v27-29 virus). Replication of both mutant viruses was comparable to that of the WT virus in four mammalian cell lines, except in Neuro2a cells. However, using confocal microscopy, HVEM protein expression was reduced in v27-29-infected Neuro2a cells, with no gD colocalization observed. Although Neuro2a cells infected with the single gD v27 mutant also showed less HVEM-gD colocalization than Neuro2a cells infected with WT virus, gD protein levels were not affected. RT‑PCR analysis of Neuro2a cells infected with single and triple gD mutants showed significantly less expression of viral glycoproteins (gB, gC, gD), host receptors (HVEM, nectin‑1, 3‑O‑sulfated heparan sulfate), and HVEM ligands (BTLA, LIGHT, Ltα, CD160), with the most pronounced effects observed for the triple v27‑29 mutant virus. Together, these results show that aa Q27-T29, rather than aa Q27 alone, are essential to completely block gD binding to HVEM and, consequently, affect overall receptor homeostasis. Introduction HSV‑1 is a highly prevalent human pathogen that establishes lifelong infection and recurrent disease [1,2]. Ocular HSV infection can progress to herpes stromal keratitis (HSK), a chronic immune‑inflammatory corneal disease that is a significant cause of infectious blindness [3–5]. Primary HSV infection is initiated through coordinated interactions between viral glycoproteins and host entry receptors on epithelial or mucosal cells that mediate attachment, entry, and immune responses [6–8], including those of the corneal surface [4,9,10]. Viral spread to the trigeminal ganglia (TG) then occurs, where latency is established in sensory neurons and sporadic reactivation drives repeated corneal inflammation and tissue damage [2,11,12]. Despite extensive knowledge of HSV infection processes, the immunological consequences of HVEM-gD engagement in viral infection remain poorly defined. An important HSV glycoprotein, gD, plays a key role in virus infection and pathogenesis as a major inducer and target of humoral and cell-mediated immune responses [13–21]. Cellular receptors for gD include nectin-1 [22,23], HVEM [24–26], and 3-OS-HS [23]. gD is the primary viral protein that engages the HVEM receptor during primary HSV infection [26]. The contact between gD amino acids (aa) 27–29 and HVEM aa 35–37 produces a β‑sheet interface stabilized by hydrogen bonds, van der Waals interactions, and electrostatic forces. This gD-HVEM complex mimics the interaction between HVEM and the B and T lymphocyte attenuator (BTLA) [27], thereby allowing the virus to directly access NF-κB-dependent cell survival pathways through HVEM. We previously showed that LAT upregulates HVEM via sncRNA1 and sncRNA2, while other gD receptors, such as nectin-1 and 3-OS-HS, remained unchanged during latency, suggesting a significant role for HVEM in latency establishment and reactivation [28,29]. HVEM is distinct in that it serves as both an entry receptor and a regulator of the host immune response. As a member of the TNF receptor superfamily, HVEM orchestrates a signaling balance between stimulatory and inhibitory pathways by engaging ligands such as LIGHT (TNFSF14), lymphotoxin-α (LTα), BTLA, and CD160 [30–34]. HVEM is selectively upregulated during latency, and both HSV latency and reactivation are significantly attenuated in HVEM-/- mice compared with WT control mice [28]. Deletion of BTLA, LIGHT, LTα, or CD160 impairs efficient establishment of latency without significantly altering reactivation [35,36], suggesting that HSV-1 specifically exploits HVEM itself rather than its standard signaling partners to promote reactivation. Such specificity indicates a structural basis for HSV-1 gD stabilization or for HVEM dysregulation independent of endogenous ligands. Thus, LAT-dependent upregulation of HVEM enhances gD's interaction with HVEM and promotes both primary and latent HSV-1 infections. To determine the structural basis of this interaction, we performed co-IP assays in HEK293T cells expressing mouse HVEM with either WT or mutant gD constructs that block HVEM binding. Mutation of a single gD aa, Q27 (Q27P), reduced HVEM binding, while triple-aa mutations (Q27A-L28A-T29A) completely blocked it. We generated recombinant HSV-1 mutants carrying these substitutions (v27 with Q27P and v27-29 with Q27A-L28A-T29A) in a GFP-McKrae background and verified them by whole genome sequencing. These gD mutant viruses are replicated comparably in several mammalian cell lines but differ in Neuro2a cells. Strikingly, viral glycoproteins and host HVEM receptor expressions were significantly reduced in the mutant viruses, with the triple v27-29 virus showing the most pronounced effect. Together, these results clearly indicate that gD-HVEM interactions extend beyond viral entry to influence receptor stability and expression. Results Mutation of gD aa 27-–29 completely abolishes binding to HVEM Mutating aa glutamine at gD position 27 to a proline has been shown to eliminate gD binding to HVEM [24,37]. This group also reported that gD aa that mediate contact with HVEM is clustered near the intermolecular antiparallel β‑sheet interface that is stabilized by hydrogen bonds between gD aa 27–29 and HVEM aa 35–37. Because a single mutation at aa Q27 can shift receptor usage from HVEM toward nectin‑1, it is reasonable to propose that additional mutations within aa 27–29 could affect binding to both HVEM and nectin‑1, given that each receptor engages overlapping gD surfaces, although the precise contributions to each receptor interface may differ. Based on this information, we generated two transgenic mouse strains in an HVEM−/− mouse background using mutated forms of mouse and human HVEM [29]. Infection of these mice, along with their controls, suggested that more than one discrete region of gD may contribute to HVEM binding. To map sites on viral gD that are necessary for its interaction with HVEM, we created three gD constructs: a full-length WT-gD open reading frame (ORF) tagged with myc (WT-gD), a single-point mutant with a Q27P substitution (glutamine to proline), and a triple mutant with Q27A-L28A-T29A substitutions. A full-length mouse HVEM ORF with dual Flag tags was also created, and all constructs were cloned into a pcDNA3.1 vector. HEK293T cells were co-transfected with mouse HVEM-2xFlag and either WT-gD, Q27P-gD, or Q27A-L28A-T29A-gD plasmids. Protein interactions were examined by anti-Flag IP followed by anti-gD Western blot. WT-gD showed strong co-immunoprecipitation with HVEM (Fig 1A, IP: Flag Ab, WT-gD lane 4). The binding of Q27P-gD to HVEM was less than that of WT-gD, but not completely abolished (Fig 1A, IP: Flag Ab, Q27P-gD lane 5), whereas the binding of Q27A-L28A-T29A-gD was undetectable (Fig 1A, IP: Flag Ab, Q27A-L28A-T29A-gD lane 6). No gD signal appeared in IgG control IPs from cells transfected with any construct (Fig 1A, IP: IgG Ab lanes 7–9). These results suggest that rather than a single aa, HVEM binding requires coordinated interactions across the Q27-L28-T29 motif in the gD N-terminus. gD mutations at aa 27–29 abolish binding to HVEM in vitro. HEK293T cells were transfected with mouse HVEM-2xFlag and either WT-gD, Q27P-gD, or Q27A-L28A-T29A-gD DNA plasmids at a 1:1 ratio for 24 hr. A) Co-immunoprecipitation showing reduced gD binding to HVEM in vitro. Cellular lysates were incubated with anti-Flag antibody bound to IgG beads, and the resulting immunoprecipitated was analyzed by western blot with anti-myc antibody; and B) Confocal microscopy showing gD mutations at aa 27–29 (3X) abolish binding to HVEM in vitro. HEK293T cells were transfected with plasmids encoding HVEM-2xFlag and either WT-gD, Q27P-gD, or Q27A-L28A-T29A-gD tagged with myc for 72 h. Transfected cells were fixed, immunostained with anti-myc and anti-Flag antibodies, and analyzed by confocal microscopy (see Materials and Methods). Panels show representative transfected HEK293T cells. Scale bar, 25 μm. To confirm the pull-down experiments described in Fig 1A, HEK293T cells were transfected with HVEM-2xFlag + WT-gD myc, HVEM-2xFlag + Q27P-gDmyc, or HVEM-2xFlag + Q27A-L28A-T29A-gDmyc for 72 hr as described in Materials and Methods. Transfected cells were fixed and immunostained with anti-myc and anti-Flag antibodies. WT-gD strongly co-localized with HVEM (Fig 1B, merge WT-gD + HVEM panel); binding of Q27P-gD to HVEM was less than that of WT-gD (Fig 1B, merge of Q27P-gD + HVEM panel), and binding of Q27A-L28A-T29A-gD to HVEM was not detectable compared to either WT or Q27P-gD (Fig 1B, merge of Q27A-L28A-T29A-gD + HVEM panel). These imaging data were supported by colocalization quantification in HALO. In S1A Fig, the colocalized area between Q27A-L28A-T29A-gD and HVEM was significantly reduced relative to WT-gD and HVEM (S1A Fig, WT to Q27A-L28A-T29A-gD, P = 0.0067, one-way ANOVA). Although a decreasing trend was observed, there was no significant difference between Q27P-gD and Q27A-L28A-T29A-gD (S1A Fig, Q27P to Q27A-L28A-T29A-gD, P > 0.05, one-way ANOVA). To determine whether co-transfection of WT or mutant gD constructs with HVEM affected protein expression, we quantified the average expression of gD and HVEM across the sections. In S1B Fig and S1C, the expression levels of gD and HVEM, respectively, did not differ significantly among groups (P > 0.05, one-way ANOVA). These results confirmed that mutations in aa 27–29 of gD blocked gD binding to HVEM, while a single mutation in aa 27 of gD significantly reduced but did not eliminate gD binding to HVEM. Construction of recombinant viruses v27 and v27‑29 expressing Q27P or Q27A-L28A-T29A, respectively, in the GFP‑McKrae background Based on mapping studies (Fig 1), we asked whether the complete loss of gD-HVEM binding affects viral replication and gene expression in vitro. To introduce Q27P or Q27A-L28A-T29A mutations into the viral gD coding region, plasmids containing GFP-gD mutations were synthesized (designated pUC57-GFP-Q27P-gD and pUC57-GFP-Q27A-L28A-T29A-gD), and co-transfected with WT-McKrae genomic DNA to generate mutant viruses that incorporate either single (Q27P-gD) or triple (Q27A-L28A-T29A -gD) substitutions, as we have reported [38–41]. GFP-positive recombinant viruses were plaque-purified five times to ensure genetic homogeneity, and two mutant viruses were isolated, v27 (Q27P) and v27-29 (Q27A-L28A-T29A) (Fig 2). Whole genome sequencing confirmed that the expected mutations in the gD ORF of v27 (Fig 2B) and v27-29 (Fig 2C) were present, with no unintended mutations or deletions elsewhere in the genome (Fig 2A). Complete genome sequences of v27 (GenBank accession PX763612) and v27-29 (GenBank accession PX837190) have been deposited, and are publicly available, in the NCBI GenBank. WT GFP-McKrae, as well as v27 and v27-29 viruses, are identical to their parental McKrae without GFP expression [40]. Schematic diagram of HSV-1 recombinant viruses. (A) GFP-McKrae virus genome in the prototypic orientation showing wild-type gD. TRL and IRL represent terminal and internal (or inverted) long repeats, respectively. TRS and IRS represent terminal and internal (or inverted) short repeats, respectively. UL and US represent long and short unique regions, respectively. gD gene: gray arrow. GFP: green arrow upstream of gD; (B) v27 virus. Schematic diagram of v27 virus is similar to “A”, showing Q27P mutation as a vertical red line in gD ORF; and (C) v27-29 virus. Schematic diagram of v27-29 virus as “A” but with three mutations in Q27A-L28A-T29A of gD and vertical red lines in gD showing the position of the Q27A-L28A-T29A mutations in gD ORF. v27 and v27-29 have similar replication kinetics in different fibroblast or epithelial cell lines To determine if partial or complete blocking of gD binding to HVEM affects virus replication in vitro, Rabbit Skin (RS) cells, HeLa, L929, and mouse embryonic fibroblast (MEF) cells were infected with 0.1 or 1 pfu/cell of WT, v27, or v27-29 viruses for 12, 24, or 48 h. Virus titers in these infected cells were determined by standard plaque assay. No significant differences were detected between the three viruses in RS cells infected with 0.1 or 1 pfu/ cell (Fig 3A, 3B; P > 0.05), HeLa cells (Fig 3C, 3D; P > 0.05), L929 cells (Fig 3E, 3F; P > 0.05), or MEF cells (Fig 3G, 3H; P > 0.05). These results show that insertion of Q27P or Q27A-L28A-T29A mutations in gD does not substantially affect virus replication in RS, HeLa, L929, or MEF cells. This is consistent with our current understanding of HSV receptor usage, in which alternate entry receptors can partially compensate for the loss or absence of a single receptor [42]. Replication of gD mutant viruses in vitro. Subconfluent Rabbit Skin, L929, HeLa, and MEF cell monolayers were infected in triplicate with 0.1 or 1 pfu/cell of WT, v27, and v27-29 viruses for 12, 24, and 48 hr, as described in the Materials and Methods. Panels: A and B (RS cells at 0.1 (A) and 1 (B) pfu/cell); C and D (HeLa cells at 0.1 (C) and 1 (D) pfu/cell); E and F (L929 cells at 0.1 (E) and 1 (F) pfu/cell); and G and H (MEF cells at 0.1 (G) and 1 (H) pfu/cell). The total virus was harvested at the indicated hr PI after two freeze-thaw cycles. Viral titers were quantified by standard plaque assays on RS cells. Each point represents the mean ± SEM from three separate experiments. Replication kinetics of v27 and v27-29 differ in neuronal cells The above results, in parallel with our in vitro data, suggest that partial or complete reduction of gD binding to HVEM does not affect gD binding in infected fibroblasts or epithelial cells. Therefore, we asked if partial or complete blocking of gD binding to HVEM affects virus replication in vitro. Neuro2a cells were infected with 0.1 or 1 pfu/cell of WT, v27, or v27-29 virus for 12, 24, or 48 hr, and virus titers in infected cells were determined by standard plaque assay. At a multiplicity of infection (MOI) of 0.1 per cell, v27 and v27-29-infected Neuro2a cells had markedly lower virus yield than WT virus at 48 hr post infection (PI). However, v27 and v27-29 viruses had similar virus titers at 12 or 24 hr PI (Fig 4A, P > 0.05, two-way ANOVA). At an MOI of 1, v27-29 virus yield was lower than that of v27 and WT viruses (although the difference was not significant), which had similar yields at 48 hr PI, while v27 and WT virus yields were similar (Fig 4B, P > 0.05, two-way ANOVA). These late-phase differences suggest that the v27-29 mutation primarily impairs secondary infection and cell-to-cell spread rather than initial entry, consistent with the timing of gD-HVEM binding as an early event. Replication of gD mutant viruses in Neuro2a cells. Subconfluent Neuro2a cell monolayers were infected in triplicate with at an MOI of 0.1 (Panel A) or 1 pfu/cell (Panel B) of WT, v27, and v27-29 viruses for 12, 24, and 48 hr, as above. Total virus was harvested at indicated times PI by two freeze-thaw cycles. Viral titers were quantified by standard plaque assays on RS cells. Each point represents the mean ± SEM from three separate experiments. These results demonstrate that replication of v27 and v27-29 viruses in Neuro2a cells was less than that of the WT virus at an MOI of 0.1 (Fig 4A), while at an MOI of 1, at 48 hr PI (Fig 4B), replication of v27 and WT viruses was 13 times higher than that of v27-29. These results suggest that complete reduction of gD binding to HVEM in the v27-29 virus reduced viral replication in neuronal cell culture. This is important because HSV establishes latency and undergoes reactivation in the TG, which is also of neuronal origin. Absence gD and HVEM colocalization in v27-29 but not v27-infected cells Our co-IP and microscopy results from the co-transfection experiment showed reduced gD binding to HVEM with the Q27P mutant and a complete loss of binding with the Q27A–L28A–T29A mutant (Fig 1B). To determine if Q27P and Q27A-L28A-T29A mutations similarly affect cell-surface localization of gD and HVEM in infected cells, Neuro2a cells were infected with v27, v27-29, and WT viruses at 1 pfu/cell for 24 and 48 hr PI (Fig 5). Subcellular localization of live infected cells was assessed by immunostaining for HVEM and gD expression and examined by confocal microscopy. Given that the gD-HVEM interaction occurs at the membrane of infected cells, live cells were stained and then fixed to assess only surface protein expression. For analysis, 8–10 z-stacks per field were acquired, and maximum-intensity projections were generated to visualize representative expression patterns. The GFP channel was used to identify the virus-positive cells. While GFP is expressed in the viruses, HVEM and gD are stained with different colors. The signals are red and green in the figures to better see the overlap. At 24 hr PI, less HVEM expression was seen in cells infected with v27 and v27-29 than in WT-infected cells, with v27-29 showing the lowest HVEM levels (Fig 5, HVEM panels). Similar gD expression was seen in WT and v27-infected cells but not in v27-29-infected cells at 24 hr PI (Fig 5, gD panels). Merging gD and HVEM images for each virus showed that gD and HVEM co-localized on the surface of WT-infected cells. gD binding to HVEM was reduced in v27-infected cells, while no colocalization was seen in v27-29-infected cells (Fig 5, Merge panels). Detection of gD and HVEM expression on the surface of infected cells at 24 hr. Subconfluent Neuro2a cell monolayers were infected with 1 pfu/cell of WT, v27, or v27-29 viruses for 24 hr. Live-infected cells were immuno-stained with anti-gD and anti-HVEM antibodies and fixed with 4%PFA as described in the materials and methods. Images were acquired by confocal microscopy as described in Materials and Methods. Panels show representative infected Neuro2a cells. Scale bar, 50 μm. Consistent with 24 hr results, at 48 hr PI, HVEM expression was reduced, with more reduction in v27-29-infected cells than in WT-infected cells (Fig 6, HVEM panels). Similarly, gD expression was reduced in the mutant groups, with more reduction in v27-29-infected cells than in WT-infected cells (Fig 6, gD panels). Similar to 24 hr PI results, merging gD and HVEM for each virus showed that gD and HVEM were localized on the surface of WT-infected cells; surface localization was reduced in v27-infected cells, and no binding was detected in v27-29-infected cells (Fig 6, Merge panels). Detection of gD and HVEM expression on the surface of infected cells at 48 hr. Subconfluent Neuro2a cell monolayers were infected with 1 pfu/cell of WT, v27, or v27-29 viruses for 48 hr. Live-infected cells were immuno-stained with respective antibodies as mentioned in Fig 5. Scale bar, 50 μm. These results align with previous findings, suggesting that WT-gD helps maintain HVEM expression and surface abundance, whereas mutant gD does not. In addition, complete blocking of gD binding to HVEM required mutations at aa 27–29, not just aa 27, which significantly, but not completely, blocks gD binding. Thus, our results suggest that gD binding to HVEM is required to upregulate HVEM. Effect of single or trip gD mutations on HSV-1 transcripts To further examine the effect of Q27P or Q27A-L28A-T29A mutations on the expression of viral transcripts, Neuro2a cells were infected with 1 pfu/cell of WT, v27, or v27-29 viruses for 24 and 48 hr. We measured gB, gC, and gD transcript levels by qRT-PCR to determine whether the Q27P and Q27A-L28A-T29A mutations selectively alter viral glycoprotein gene expression during infection at early and late time points. The gD copy number was lower in v27- and v27-29-infected cells than in WT-infected cells at 24 hr PI, but the differences were not statistically significant (Fig 7A, 24 hr, P > 0.05). In contrast, gD transcripts were significantly higher in WT-infected control cells at 48 hr PI than in v27 (Fig 7A, 48 hr, P < 0.0115) and v27-29-infected cells (Fig 7A, 48 hr, P < 0.0155). No differences in gD expression were in v27 and v27-29-infected cells (Fig 7A, 48 hr, P > 0.05). As with gD expression (Fig 7A), the patterns of gB (Fig 7B) and gC (Fig 7C) expression were similar at 24 hr PI. The expression of gB was significantly reduced in v27-, and v27-29-infected cells compared to the WT virus-infected cells at 24 hr PI (Fig 7A, 24 hr, P = 0.0126). At 48 hr PI, gB expression showed a reduction trend for v27 and v27-29-infected cells compared to WT virus-infected cells (Fig 7B, 48 hr, P > 0.05). Notably, expression of gC showed a significant reduction in v27-infected cells (Fig 7C, 24 hr, P = 0.002), and v27-29-infected cells (Fig 7C, 24 hr, P = 0.0454) at 24 hr PI. At 48 hr PI, expression of gC showed a significant reduction in v27-infected cells (Fig 7C, 48 hr, P = 0.0014), and v27-29-infected cells (Fig 7C, 48 hr, P = 0.0031). There was no significant difference between v27 or v27-29 viruses at any time points (Fig 7A-7C, P > 0.05). These results demonstrate that both Q27P and Q27A-L28A-T29A mutations selectively and significantly alter viral glycoprotein gene expression in vitro, without affecting gD protein expression. The mutant viruses showed altered mRNA expression of viral genes yet produced only slightly reduced titers, suggesting that the remaining replication steps- DNA replication, protein translation, virion assembly, egress, and infectivity of released particles- were largely preserved if the changes in one step are compensated by others. Effect of gD binding to HVEM on viral gene expression. Subconfluent Neuro2a cell monolayers were infected with 1 pfu/cell of WT, v27, or v27-29 viruses for 24 or 48 hr, as described in Materials and Methods. Total RNA was isolated from infected Neuro2a cells, and quantitative TaqMan qRT-PCR was performed on total RNA. In each experiment, the estimated relative copy number of gD, gB, or gC was calculated using standard curves generated from pAc-gD1, pAc-gB1, and pAc-gC1 plasmids. Each point represents the mean ± SEM from three separate experiments. Effect of gD mutations on expression of its receptors (HVEM, Nectin-1, and 3-OS-HS) in infected cells We have reported that HSV-1 upregulates HVEM but no other known HSV-1 receptor [28,29]. Because our previous studies suggested that LAT is involved in HVEM upregulation, we asked whether the absence of v27 or v27-29 binding to HVEM affects expression of the gD receptors, HVEM, nectin-1, or 3-OS-HS. Neuro2a cells were infected with 1 pfu/cell of WT, v27, or v27-29 viruses for 24 or 48 hr, and HVEM, nectin-1, and 3-OS-HS mRNA levels were measured by qRT-PCR. The results are shown as fold change in gene expression relative to mock-infected cells. At 24 hr PI, HVEM expression was similar among the three infected and mock groups (Fig 8A, 24 hr PI, P > 0.05). In contrast, expression of HVEM in v27 or v27-29-infected cells was significantly lower than that in WT-infected cells at 48 hr PI (Fig 8A, P < 0.0001, 48 hr PI). Notably, HVEM expression was lower in v27‑29-infected cells than in v27-infected cells at 48 hr PI (Fig 8A, P = 0.002). Nectin-1 expression was markedly lower in v27- (Fig 8B, P = 0.0105) infected cells at 24 hr PI, than in WT-infected cells. At 48 hr PI, nectin-1 levels were significantly lower in v27-29-infected cells than in v27- or WT-infected cells (Fig 8B, P = 0.0407). No significant differences in 3-OS-HS expression were observed among the three infected groups at 24 hr PI (Fig 8C, 24 hr, P > 0.05), whereas its expression was significantly lower in v27-29 than in WT (Fig 8C, P < 0.0071) infected cells at 48 hr PI. Effect of gD binding to HVEM on expression of gD-associated receptors in infected cells. RNA isolated from infected cells described in Fig 6 was used to measure expression of HVEM, nectin-1, and 3OS-SH by qRT-PCR. Relative expression levels were normalized to GAPDH and calculated relative to mock-infected cells. Each point represents the mean ± SEM from three separate experiments. These results further demonstrate that both Q27P and Q27A-L28A-T29A mutations affect host receptor expression, with the greatest reduction in receptor expression observed in the v27-29 triple-mutant virus. In contrast to previous reports suggesting that the Q27P mutation in HSV gD enables the virus to adapt to nectin‑1 in the absence of HVEM [24,25]. We found that altering gD aa 27–29 disrupts and may even impair the virus’s ability to use both HVEM and nectin‑1 as entry receptors. Effect of blocking gD binding to HVEM on other members of the TNF receptor superfamily In addition to HVEM, LIGHT (TNFSF14), lymphotoxin-α (LTα), CD160, and BTLA are also members of the TNF receptor superfamily [32,34]. They act as a molecular switch between proinflammatory and inhibitory signaling to regulate homeostasis [43,44]. In addition to gD, HVEM is activated by LIGHT (TNFSF14), lymphotoxin-α (LTα), CD160, and BTLA [26,43,44]. To determine if Q27P and Q27A-L28A-T29A mutations also affect HVEM-ligand expression, Neuro2a cells were infected with WT, v27, or v27-29 viruses at 1 pfu/cell, and levels of BTLA, LIGHT, lymphotoxin-α, and CD160 mRNA were measured by qRT-PCR at 24 and 48 hr PI. At 24h, the relative expression of BTLA and LIGHT was similar among cells infected with the three viruses (Fig 9A-9B, P > 0.05). A similar trend in expression was observed for lymphotoxin-α (Fig 9C, 24 hr, P > 0.05) and CD160 (Fig 9D, 24 hr, P > 0.05). Effect of gD binding to HVEM on TNF superfamily expression in infected cells. RNA isolated from infected cells (as described in Fig 6) was used to measure expression of BTLA, LIGHT, Ltα, and CD160, as described in the Materials and Methods. Relative expression was normalized to GAPDH and calculated relative to mock-infected cells. Each point represents the mean ± SEM from three separate experiments. At 48 hr PI, BTLA and LIGHT expression were both increased in WT cells than in v27- and v27-29-infected cells, although the difference was not significant (Fig 9A-9B, P > 0.05), but v27- and v27-29-infected cells did not differ significantly (Fig 9A-9B, P > 0.05). At 48 hr PI, lymphotoxin-α expression in WT-infected cells was significantly increased compared to v27- (Fig 9C, P = 0.0293) and v27-29-infected cells (Fig 9C-9D, P = 0.0242). Notably, at 48 hr PI, v27‑29-infected cells expressed less lymphotoxin-α than did v27-infected cells (Fig 9C, P = 0.0123). In addition, CD160 levels showed a similar reduction in the mutant viruses compared to the WT virus (although the differences were not significant; Fig 9D, 48 hr, P > 0.05). The expression was similar between v27- and v27-29-infected cells (Fig 9D, 48 hr, P > 0.05). These results suggest that Q27A-L28A-T29A mutations profoundly affect host receptor expression and HVEM-ligand levels. Discussion The HSV-1 gD gene is essential, with homologs that are highly conserved in different HSV-1 strains (i.e., KOS, F, McKrae, 17, H129, SC, ANG) [45–48]. gD plays a key role in virus infection and pathogenesis by binding to the cellular HVEM receptor, thereby influencing HSV‑1 latency and reactivation in corneal epithelium, immune cells, and neurons. gD is a major inducer and target of humoral and cell-mediated immune responses following infection [49,50], mediated by its binding to HVEM, nectin-1, and 3-OS-HS [6,24,37,51–53]. In previous studies, mutations at two sites within the gD N-terminal loop were shown to alter receptor usage [24,37,53]. Substitution of gD-L25 with proline, or gD-Q27 with proline or arginine, permitted the use of the nectin-2 receptor for virus entry [37,54]. Single-amino-acid substitutions in gD, specifically Q27P and Q27R, allow the virus to resist gD-mediated interference [37]. These mutations impair entry via the HVEM receptor while enabling or enhancing entry via other receptors, such as nectin-2, thereby altering the virus's ability to infect different cells. Introduction of the Q27P mutation into gD interfered with its ability to interact with HVEM, resulting in a 10-fold greater affinity for nectin-1 [24]. A subsequent study showed that a gD-1 (delta290-299t) mutant similarly blocks HVEM entry while preserving nectin-1 function [53]. Because most of the above studies used less virulent viruses, we generated recombinant viruses using the highly virulent ocular HSV-1 strain McKrae. Before creating mutant gD viruses in McKrae that do not bind to HVEM, we performed mapping studies and found that substitution of glutamine with proline at aa 27 of gD significantly, but not completely, reduced its binding to HVEM, whereas a Q27A-L28A-T29A triple mutation completely abolished this interaction. Despite these substantial changes in receptor engagement, the replication kinetics of v27 and v27-29 were similar to those of the WT virus in four different mouse, rabbit, and human epithelial cell lines. However, replication of the two viruses differed from WT virus in Neuro2a cells, which share a neuronal origin. Similar growth curves indicate that alternate gD receptors, such as nectin-1 and 3-OS-HS, can compensate for reduced HVEM binding to sustain productive replication. Although both nectin-1 and HVEM are expressed in cells and neurons, HSV-1 preferentially uses nectin-1 for both neuronal and epithelial cell entry. For example, antibodies against nectin-1, but not against HVEM, inhibit HSV-1 entry into cultured neurons [55] and epithelial cells [56]. Additionally, mutations in gD that inhibit its binding to nectin-1 prevent infection of neurons, whereas mutations that eliminate crucial HVEM binding sites in gD do not [57]. Our results are consistent with previous findings that HSV-1 mutants that cannot bind HVEM (e.g., Rid1) replicate similar to the WT virus in nectin-1-expressing cells, such as Vero and HEp-2, but have profound entry defects in HVEM-dependent Chinese hamster ovary cells [58]. These results indicate that disrupting a single receptor pathway often has only minor effects on acute viral titers when other receptors remain available. In addition to HVEM, v27-29-infected cells also had reduced nectin-1 and 3-OS-HS expression at 48 hr PI. Similar to our previous study [28], Neuro2a cells infected with WT virus showed higher HVEM expression than those infected with v27 or v27-29. However, a similar pattern of nectin-1 and 3-OS-HS expression was not detected. Reduced replication of v27 and v27-29, especially v27-29, in Neuro2a cells positively correlated with viral gene expression, as gB, gC, and gD expression were significantly reduced in infected Neuro2a cells. Reduced expression of HVEM, nectin-1, and 3-OS-HS in Neuro2a cells infected with v27 and v27-29 suggests a broader regulatory role for gD in shaping the neuronal receptor landscape. HVEM expression was not increased in v27- or v27-29-infected cells compared with the higher levels observed in WT-infected cells, parallels the degree of impairment in gD-HVEM binding observed in pull-down assays, supporting a direct mechanistic link between physical interaction and steady-state receptor expression. Consistent with our previous works [28,29], we found that LAT(+) viruses upregulate HVEM transcription in TG neurons via NF-κB signaling, while HVEM-/- mouse studies confirmed that host HVEM promotes viral reactivation independent of LAT, and that LAT itself upregulates neuronal HVEM to enhance reactivation efficiency. Concomitant downregulation of nectin-1 and 3-OS-HS suggests that loss of gD-HVEM binding may modulate cellular pathways that govern expression or stability of multiple viral entry receptors, potentially through HVEM-associated signaling cascades. Similar to gD, HVEM is a ligand for BTLA, LIGHT, and LTα and can block each in a ligand- and epitope-specific manner [42,44]. gD directly competes with BTLA for HVEM binding, but not with LIGHT or LTα, which reflects their overlapping (HVEM) and non-overlapping (LIGHT, LTα) binding footprints on HVEM [42]. Our results suggest that gD binding to HVEM is required to upregulate HVEM and the HVEM pathway. In contrast, we previously reported that LAT upregulates HVEM but not other members of the TNF superfamily [28]. The absence of major differences in viral replication across these diverse cell lines confirmed that the mutant viruses retain comparable growth capacity in vitro under non-selective conditions. Subsequently, the lack of upregulation of the HVEM ligands BTLA, LIGHT, Ltα, and CD160 suggests that canonical HVEM signaling was not enhanced in the absence of gD binding, compared with WT gD expression, where significant upregulation of these genes was observed. Both complete loss and partial reduction of gD binding to HVEM were associated with significantly reduced transcription of BTLA, LIGHT, Lta, and CD160 compared with WT. HVEM is activated by binding to LIGHT and Ltα and binds to CD160 and BTLA [32,43,44]. In this context, WT-gD may function not only as a viral ligand that exploits HVEM for entry but also as a modulator of host receptor expression that promotes a receptor milieu favorable for recurrent infection. In contrast, gD mutants that do not efficiently engage HVEM, fail to maintain this permissive state. These findings suggest that the transcriptional regulation of this ligand-receptor axis is differentially influenced by the two mutant viruses, which may reflect distinct effects of the viral mutations on immune modulatory signaling. Our pull-down assays using transfected cells showed that a single mutation in gD aa 27 reduced its binding to HVEM by approximately 80%, while mutations in gD aa 27–29 completely blocked its binding to HVEM. This discrepancy between our results and those of previous studies [24,37] is likely due to the use of different binding assays. Thus, to confirm our pull-down assays showing partial-to-complete gD binding to HVEM, we asked whether cells infected with the v27 and v27-29 viruses showed similar results. We examined cell-surface expression and gD binding in infected cells using both unfixed and fixed cells. As expected, WT-gD from WT-infected virus binds to HVEM on the surface of infected cells when HVEM and gD staining were co-localized. In v27-infected cells, we saw significantly less staining of co-localized HVEM and gD, while gD and HVEM did not co-localized in v27-29-infected cells. These results support our overall hypothesis that aa 27–29, but not aa 27 alone, is required to completely block gD binding to HVEM. These results also suggest that gD-HVEM engagement not only mediates receptor-dependent entry but also positively regulates HVEM abundance at the neuronal surface, to potentially establish a feed-forward loop that favors efficient gD-HVEM signaling during infection and reactivation. The results of this study support a model in which specific gD aa that governs HVEM binding, also fine-tune HSV-1 interactions with neuronal receptors, without significantly altering lytic replication in vitro. In this context, v27 and v27-29 viruses provide useful tools to determine how specific changes in gD-HVEM binding alter latency and reactivation dynamics in vivo. Future in vivo studies will be needed to determine whether targeting the gD Q27-T29 region, or downstream HVEM-dependent signaling, can selectively reduce HSV-1 reactivation without substantially compromising control of primary infection. Materials and methods Cells and viruses RS cells were used to prepare virus stocks, culture mouse tear swabs, and determine viral growth kinetics. RS cells were grown in Eagle’s minimal essential medium supplemented with 5% fetal bovine serum. Triple plaque-purified HSV-1 WT, v27, and v27-29 viruses were used in this study. HEK293T, HeLa, L929, Neuro2a, and Mouse embryonic fibroblast (MEF) cells were cultured in DMEM medium supplemented with 10% FBS. Co-immunoprecipitation We generated three gD constructs: a full-length WT-gD ORF with a myc tag (WT-gD), a single-point mutant plasmid containing a Q27P substitution with a myc tag, and a triple mutant containing Q27A-L28A-T29A substitutions with a myc tag. We also generated a full-length mouse HVEM ORF with dual Flag tags (HVEM-2xFlag). All constructs were cloned into the pcDNA3.1 vector as we described previously [59]. HEK 293T cells were seeded in 10 cm tissue culture dishes at 4.4 x10^6 cells/dish. Next day, cells were transfected with 10ug mouse HVEM 2XFlag plasmid and 5 ug of one of the gD constructs. Cells were lysed in 0.9 ml lysis buffer (100mM NaCL, 20mM Tris HCL, pH 7.4, 1% NP-40, protease inhibitor cocktail (Roche Life Sciences, Penzberg, Germany) 24 hr post-transfection. Lysates were incubated on ice for 30 min and then cleared by centrifugation for 10 min at 13,000 rpm at 4°C. 70 uL lysate was saved for input, and 70 uL 2X-LDS sample buffer (NuPage LDS sample buffer, Invitrogen cat # NP0007) supplemented with 5% mercaptoethanol (Fluka) was added. Lysate was added to Protein G Dynabeads (Dynabeads Protein G, Invitrogen, cat # 10003D) or Anti-DYKDDDDK magnetic agarose beads (Pierce, cat # A367997) and incubated overnight with rotation at 4 °C. Samples were then washed 3 times, 5 minutes each, in lysis buffer. 50 uL LDS sample buffer was added to the washed beads to elute bound proteins. Samples were incubated at 75˚C for 10 minutes. Proteins were separated by SDS-PAGE, followed by transfer to nitrocellulose membrane. Membrane was blocked using 5% non-fat dry milk in PBST and incubated with primary antibodies (Mouse anti-gD Abcam cat #: Ab 6507, 1:1000 dilution for WB; Mouse anti Flag M2 Sigma Cat # F1804, 1:1000 dilution; Purified Rat anti DYKDDDK clone L5, Biolegend cat # 637301, 1:500) followed by HRP conjugated secondary antibodies (Goat anti mouse IgG secondary antibody, HRP Invitrogen cat # 62–6520; Biolegend Goat anti Rat IgG clone Poly 4054 cat # 405405). Images were acquired using FluorChem E (Protein Simple, San Jose, CA). Construction of gD mutant viruses Previously, we constructed a recombinant HSV-1 virus expressing GFP upstream of gD in a WT-McKrae background, referred to as GFP-McKrae [40]. Based on WT-McKrae nucleotides 136441–139321, we synthesized two plasmids: one with a single aa mutation in gD aa 27 (Q27P); and the second with three aa mutations (Q27A-L28A-T29A). Both plasmids contain a complete GFP sequence under the control of a cytomegalovirus (CMV) promoter, flanked by two unique Pac1 sites (GenScript, Piscataway, NJ). These constructs were inserted into the pUC57 Pac1 site, and the resulting plasmids were designated pUC57-Q27P-gD and pUC57-Q27A-L28A-T29A-gD. Recombinant viruses v27 (Q27P mutation) and v27-29 (Q27A-L28A-T29A) were generated by co-transfecting pUC57-Q27P-gD or pUC57-Q27A-L28A-T29A-gD together with infectious McKrae DNA using the calcium phosphate method as described [40,60–62]. Viruses from the co-transfection were plated, and isolated plaques were picked and screened for GFP expression as we described [40]. Selected plaques with GFP gene expression were plaque-purified five times. Presence of the expected gD mutations was confirmed by PCR and next-generation sequencing. Complete genome sequences of v27 (GenBank accession PX763612) and v27-29 (GenBank accession PX837190) have been deposited in GenBank. Kinetics of virus replication in tissue culture RS, L929, HeLa, MEF, and Neuro2a cell monolayers at 70–80% confluency were infected with 0.1 and 1 pfu/cell of WT, v27, or v27-29 virus. Virus was harvested at 12, 24, or 48 hr PI by subjecting cell monolayers to two freeze-thaw cycles. Virus titers were determined by standard plaque assay on RS cells, as described [63]. Co-expression of gD and HVEM in infected cells Neuro2a cells were cultured on glass coverslips, and monolayers at 80% confluency were infected with WT, v27, or v27-29 viruses at 1 pfu/cell for 24 or 48 hr. Following infection, cells were washed twice with phosphate-buffered saline (PBS) and blocked with blocking solution (2% BSA + 2% goat serum +2% milk in 0.1% PBS) for 30 minutes at room temperature. Live cells were incubated with rabbit anti-gD (Thermo Fisher Scientific, PA1–30233; 1:50) and Armenian hamster anti-mouse HVEM (Thermo Fisher Scientific, 14-5962-82; 1:100) antibodies in blocking buffer for 1 hr at room temperature. Cells were washed 3 times with 1 × PBS and incubated with goat anti-rabbit Alexa Fluor 647 (Thermo Fisher Scientific, A32733TR; 1:100) and goat anti-Armenian hamster Alexa Fluor 555 (Thermo Fisher Scientific, A78964; 1:100) secondary antibodies for 1 hour at 25 °C. Following secondary incubation, slides were washed 3 times with 1 × PBS and fixed with 4% paraformaldehyde (PFA) for 10 minutes at room temperature. Samples were mounted using ProLong Gold Antifade reagent with DAPI (Invitrogen, P36931). Images were acquired on a Leica Stellaris 8-STED super-resolution confocal microscope (Leica Microsystems, Buffalo Grove, IL). Images were processed using LAS X Office 1.4.4 software. Cells with fluorescent signals were initially identified at 20 × magnification with 16-bit resolution. Images of virus-positive regions were captured at a resolution of 1024 × 1024 pixels, with a scanning speed of 400, bidirectional scanning enabled, and a line average of 4. The GFP channel was used to identify the virus-positive cells. While GFP is expressed in the viruses, HVEM and gD are stained with different colors. The signals are red and green in the figures to better see overlapping. For analysis, 8–10 z-stacks per field were acquired, and maximum-intensity projections were generated to display representative expression patterns. HALO analysis for colocalization Immunofluorescence images were analyzed using HALO image analysis software (version 4.0.5; Indica Labs). Confocal fluorescence images were acquired using a Leica STELLARIS 8 confocal microscope with a 63 × objective. Z-stack images were imported into HALO for quantitative analysis. The DAPI channel was used to assist with nuclear identification and cell localization. Fluorescence-positive areas for each marker were defined using intensity thresholds established from negative-control slides and then applied uniformly to all experimental images. Marker-positive and co-localized regions were quantified using the HALO Area Quantification FL module. Co-localized areas were identified by overlapping marker-positive masks and were used to measure the co-expression area and mean fluorescence intensity within the flagged regions. Colocalization analysis was performed using the phenotype function in the HALO Area Quantification FL module. Positive fluorescence areas for each channel were first defined using thresholds established from negative-control images. A colocalized region was then identified by applying a phenotype criterion requiring the area to be positive for both fluorescence channels. Regions meeting this dual-positive criterion were flagged as colocalized areas, and the total colocalized area and mean fluorescence intensity within these regions were quantified for each image. RNA extraction, cDNA synthesis, and TaqMan RT-PCR Neuro2a cell monolayers at 80% confluency were infected with 0.1 or 1 pfu/cell of WT, v27, or v27-29 viruses. Infected cells were harvested at 24 or 48 hr PI. Total RNA was extracted using chloroform (Ambion, Austin, TX), purified using RNeasy columns (Qiagen, Hilden, Germany), and cDNA was synthesized as described previously [63]. Quantitative real-time PCR (qRT-PCR) was performed using custom TaqMan probe and primer sets for HSV-1 gB, gC, and gD, and the expression of HVEM, nectin-1, heparan sulfate-3-O-sulfotransferase (3-OS-HS), LIGHT, BTLA, CD160, and lymphotoxin-α was assessed in infected cells. In all experiments, GAPDH was used to normalize transcript levels. Each primer-probe set contained two unlabeled PCR primers and a FAM-labeled TaqMan minor groove binder probe, formulated as a single mixture. All cellular amplicons spanned intron-exon junctions to eliminate potential amplification of genomic DNA. The following assays were used in this study: 1) HVEM, ABI assay I.D. Mm00619239_m1 – amplicon length = 65 bp; 2) LIGHT, ABI Mm00444567_m1 – amplicon length = 68 bp; 3) BTLA, ABI Mm00616981_m1 – amplicon length = 71 bp; 4) CD160, ABI Mm00444461_m1 – amplicon length = 61 bp; 5) lymphotoxin-α, ABI Mm00440228_gH (amplicon size, 59 bp); 6) nectin-1, ABI Mm00445392_m1 (amplicon size, 71 bp); 7) 3-OS-HS, ABI Mm00479621_m1 (amplicon size, 65 bp); 8) HSV-1 gC, ABI ARCE4XE – amplicon length = 122 bp; and 9) GAPDH used to normalize transcripts, ABI Mm999999.15_G1 – amplicon length = 107 bp. Levels of gB and gD RNA from infected Neuro2a cells were determined using custom-made: 1) gB-specific primers (forward - 5’-AACGCGACGCACATCAAG-3’; reverse - 5’-CTGGTACGCGATCAGAAAGC-3’; and probe - 5’-FAM-CAGCCGCAGTACTACC-3’), with a primer amplicon length of 72 bp; and 2) a gD primer and probe set with: forward primer, 5’-GCGGCTCGTGAAGATAAACG-3’; reverse primer, 5’-CTCGGTGCTCCAGGATAAACTG-3’; and probe, 5’-FAM-CTGGACGGAGATTACA-3’, and amplicon length = 59 bp. Relative gB, gC, and gD copy numbers were calculated using standard curves generated from plasmids pAc-gB1 [64], pAc-gC1 [65], and pAc-gD1 [49]. Statistical analysis For all statistical tests, p-values less than or equal to 0.05 were considered statistically significant and are indicated by a single asterisk (*), and p-values less than or equal to 0.001 are indicated by double asterisks (**). Two-way analysis of variance (ANOVA) was used to compare differences among three or more experimental groups. All experiments were repeated at least three times to ensure accuracy. Original data: All raw data to generate the figures and the Western blot of Fig 1 are within the Supporting Information files. Supporting information gD mutations at aa 27–29 abolish binding to HVEM in vitro. HEK293T cells were transfected with plasmids encoding mouse HVEM-2xFlag and either WT-gD, Q27P-gD, or Q27A-L28A-T29A-gD tagged with Myc for 72 hr, as previously described in Fig 1. Confocal images were analyzed for colocalization using HALO software. (A) Quantification of colocalized area (μm2) for WT-gD, Q27P-gD, or Q27A-L28A-T29A-gD with HVEM. Each point represents the mean ± SEM from 5, 6, and 8 fields from HEK293T cells transfected with WT-gD, Q27P-gD, or Q27A-L28A-T29A-gD and HVEM, respectively. (B, C) Mean expression of gD and HVEM in cells transfected with WT-gD, Q27P-gD, or Q27A-L28A-T29A-gD and HVEM. (PDF) Colocalization of gD and HVEM expression on the surface of infected cells. Subconfluent Neuro2a cell monolayers were infected with 1 pfu/cell of WT, v27, or v27-29 virus for 48 hr, as described in Fig 6. Live-infected cells were immunostained with anti-gD and anti-HVEM antibodies, then fixed with 4%PFA, as described in the Materials and Methods. Colocalized area (μm2) of gD and HVEM was quantified in WT-, v27- or v27-29-infected cells. Each point represents the mean ± SEM from 15, 10, and 26 fields from WT-, v27-, and v27-29-infected cells. (PDF) Rawgel. (PNG) Data. (PDF) 10 Jul 2026 PPATHOGENS-D-26-01247 Complete Disruption of gD Binding to HVEM Alters Virus Replication and Host Receptor Homeostasis PLOS Pathogens Dear Dr. Ghiasi Thank you for submitting your manuscript to PLOS Pathogens. After careful consideration, we feel that it has merit but does not fully meet PLOS Pathogens's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. It is recommended that the Authors address all of the minor revisions made by the three reviewers. Fixing these minor concerns will improve this manuscript. Please submit your revised manuscript by Aug 09 2026 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plospathogens@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/ppathogens/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. Please include the following items when submitting your revised manuscript: * A letter that responds to each point raised by the editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'. This file does not need to include responses to any formatting updates and technical items listed in the 'Journal Requirements' section below. * A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'. * An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. If you would like to make changes to your financial disclosure, competing interests statement, or data availability statement, please make these updates within the submission form at the time of resubmission. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter. As the corresponding author, your ORCID iD is verified in the submission system and will appear in the published article. PLOS supports the use of ORCID, and we encourage all coauthors to register for an ORCID iD and use it as well. Please encourage your coauthors to verify their ORCID iD within the submission system before final acceptance, as unverified ORCID iDs will not appear in the published article. Only the individual author can complete the verification step; PLOS staff cannot verify ORCID iDs on behalf of authors. We look forward to receiving your revised manuscript. Kind regards, Clinton Jones, PhD Academic Editor PLOS Pathogens Robert Kalejta Section Editor PLOS Pathogens Sumita Bhaduri-McIntosh Editor-in-Chief PLOS Pathogens orcid.org/0000-0003-2946-9497 Michael Malim Editor-in-Chief PLOS Pathogens orcid.org/0000-0002-7699-2064 Journal Requirements: If the reviewer comments include a recommendation to cite specific previously published works, please review and evaluate these publications to determine whether they are relevant and should be cited. There is no requirement to cite these works unless the editor has indicated otherwise. 1) In the online submission form, you indicated that The original contributions presented in this study are included in the article material. Further inquiries can be directed to the corresponding author.. All PLOS journals now require all data underlying the findings described in their manuscript to be freely available to other researchers, either 1. In a public repository 2. Within the manuscript itself 3. Uploaded as supplementary information. This policy applies to all data except where public deposition would breach compliance with the protocol approved by your research ethics board. If your data cannot be made publicly available for ethical or legal reasons (e.g., public availability would compromise patient privacy), please explain your reasons by return email and your exemption request will be escalated to the editor for approval. Your exemption request will be handled independently and will not hold up the peer review process, but will need to be resolved should your manuscript be accepted for publication. One of the Editorial team will then be in touch if there are any issues. 2) Please amend your detailed Financial Disclosure statement. This is published with the article. It must therefore be completed in full sentences and contain the exact wording you wish to be published. 1) State what role the funders took in the study. If the funders had no role in your study, please state: "The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript." 2) If any authors received a salary from any of your funders, please state which authors and which funders.. If you did not receive any funding for this study, please simply state: u201cThe authors received no specific funding for this work.u201d 3) We have amended your Competing Interest statement to comply with journal style. We kindly ask that you double check the statement and let us know if anything is incorrect. 4) PLOS now requires that authors provide the original uncropped and unadjusted images underlying all blot or gel results reported in a submission’s figures or Supporting Information files. This policy and the journal’s other requirements for blot/gel reporting and figure preparation are described in detail at https://journals.plos.org/plosone/s/figures#loc-blot-and-gel-reporting-requirements and https://journals.plos.org/plosone/s/figures#loc-preparing-figures-from-image-files. When you submit your revised manuscript, please ensure that your figures adhere fully to these guidelines and provide the original underlying images for all blot or gel data reported in your submission. See the following link for instructions on providing the original image data: https://journals.plos.org/plosone/s/figures#loc-original-images-for-blots-and-gels. In your cover letter, please note whether your blot/gel image data are in Supporting Information or posted at a public data repository, provide the repository URL if relevant, and provide specific details as to which raw blot/gel images, if any, are not available. Email us at customercare@plos.org if you have any questions. Reviewers' Comments: Reviewer's Responses to Questions Part I - Summary Please use this section to discuss strengths/weaknesses of study, novelty/significance, general execution and scholarship. Reviewer #1: HSV-1 gD binds the entry receptor HVEM; however, the specific contributions of individual amino acid residues in gD to this interaction remain incompletely understood. By generating targeted viral mutants, this study convincingly demonstrates that residues Q27 and Q27-T29 in gD are critical for HVEM binding, with the triple mutant disrupting this interaction more effectively than the Q27 single mutant and resulting in reduced receptor engagement as well as altered viral and host gene expression, particularly in neuronal cells. ********** Part II – Major Issues: Key Experiments Required for Acceptance Please use this section to detail the key new experiments or modifications of existing experiments that should be absolutely required to validate study conclusions. Generally, there should be no more than 3 such required experiments or major modifications for a "Major Revision" recommendation. If more than 3 experiments are necessary to validate the study conclusions, then you are encouraged to recommend "Reject". Reviewer #1: N/A ********** Part III – Minor Issues: Editorial and Data Presentation Modifications Please use this section for editorial suggestions as well as relatively minor modifications of existing data that would enhance clarity. Reviewer #1: Figure 1B: gD-HVEM colocalization appears to occur at or near the nuclear rim, which is unusual for these proteins. Please provide clarification or add in discussion. 1A: It is unclear whether the "1× mutant" and "3× mutant" correspond exactly to Q27 and Q27-29 mutants, respectively. If so, consistent terminology should be used throughout. Figure 2: The schematics are repetitive and could be consolidated into a single panel, potentially merged with Figure 1 to improve clarity. Figure 3: Both logarithmic and linear scales are used interchangeably. A consistent approach (preferably logarithmic) is recommended; if not, please justify the rationale. Figure 4: Are the observed differences statistically significant? Please clarify. Figure 5: HVEM is supposed to be a transmembrane protein, but the authors observe strong nuclear localization (e.g., Fig. 5A, WT). This nuclear/nuclear rim localization remains puzzling and should be addressed. Figure 6: The rationale for this experiment is not clearly explained, and its significance is difficult to interpret. Additionally, one might expect differences between the Q27 and Q27-T29 mutants, please comment. ********** PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy. Reviewer #1: No [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] Figure resubmission: While revising your submission, we strongly recommend that you use PLOS’s NAAS tool (https://ngplosjournals.pagemajik.ai/artanalysis) to test your figure files. NAAS can convert your figure files to the TIFF file type and meet basic requirements (such as print size, resolution), or provide you with a report on issues that do not meet our requirements and that NAAS cannot fix. After uploading your figures to PLOS’s NAAS tool - https://ngplosjournals.pagemajik.ai/artanalysis, NAAS will process the files provided and display the results in the "Uploaded Files" section of the page as the processing is complete. If the uploaded figures meet our requirements (or NAAS is able to fix the files to meet our requirements), the figure will be marked as "fixed" above. If NAAS is unable to fix the files, a red "failed" label will appear above. When NAAS has confirmed that the figure files meet our requirements, please download the file via the download option, and include these NAAS processed figure files when submitting your revised manuscript. Reproducibility: To enhance the reproducibility of your results, we recommend that authors of applicable studies deposit laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. Additionally, PLOS ONE offers an option to publish peer-reviewed clinical study protocols. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols 17 Jul 2026 Submitted filename: Response (07-14-2026)PP.doc 4 Aug 2026 PPATHOGENS-D-26-01247R1 Complete Disruption of gD Binding to HVEM Alters Virus Replication and Host Receptor Homeostasis PLOS Pathogens Dear Dr. Ghiasi, Thank you for submitting your manuscript to PLOS Pathogens. After careful consideration, we feel that it has merit but does not fully meet PLOS Pathogens's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. Please submit your revised manuscript by Sep 03 2026 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plospathogens@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/ppathogens/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. Please include the following items when submitting your revised manuscript: * A letter that responds to each point raised by the editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'. This file does not need to include responses to any formatting updates and technical items listed in the 'Journal Requirements' section below. * A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'. * An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. If you would like to make changes to your financial disclosure, competing interests statement, or data availability statement, please make these updates within the submission form at the time of resubmission. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter. As the corresponding author, your ORCID iD is verified in the submission system and will appear in the published article. PLOS supports the use of ORCID, and we encourage all coauthors to register for an ORCID iD and use it as well. Please encourage your coauthors to verify their ORCID iD within the submission system before final acceptance, as unverified ORCID iDs will not appear in the published article. Only the individual author can complete the verification step; PLOS staff cannot verify ORCID iDs on behalf of authors. We look forward to receiving your revised manuscript. Kind regards, Robert F. Kalejta, Ph.D. Section Editor PLOS Pathogens Robert Kalejta Section Editor PLOS Pathogens Sumita Bhaduri-McIntosh Editor-in-Chief PLOS Pathogens orcid.org/0000-0003-2946-9497 Michael Malim Editor-in-Chief PLOS Pathogens orcid.org/0000-0002-7699-2064 Additional Editor Comments (if provided): Dear Dr. Ghiasi, I need to inform you of an issue with the review of this manuscript. Your original decision letter contained only a single review. However, four reviews were obtained for the original manuscript. The fact that you did not receive the other reviews appears to be a clerical error. Nevertheless, the original reviews need to be addressed. I have found your response to the comments of original reviewer #1 to be satisfactory. Below please find the other three reviews. No additional experiments appear to be required, but each reviewer does ask for clarifications and changes to the manuscript. Please address all comments of reviewers #2, #3, and #4 in a revised manuscript that will be editorially reviewed before a decision is rendered. I apologize for the confusion and delay, and hope that we can quickly provide you with a suitable resolution to this unfortunate situation. Reviewer #2 Arya and coworkers performed a series of studies to investigate with greater precision the binding of herpes simplex virus type 1 (HSV1)-encoded glycoprotein D (gD) to host cell receptor HVEM with focus on the contributions of individual amino acids to HVEM binding. Following construction of two mutant forms of HSV1 McKrae strain gD designated Q27P and Q27A – L28A – T29A that disrupt gD binding to HVEM, it was found that gD amino acids Q27 – T29 were critical for HVEM binding with the triple mutant showing greater disruption of HVEM binding than the Q27P single mutant. To further map gD binding to HVEM and assess functional relevance, two recombinant viruses were constructed on a HSV1 McKrae strain background and designated v27 virus (a single gD amino acid mutation) and v27 – 29 virus (three gD mutations). A series of in vitro studies were performed comparing the v27 virus, the v27 – 29 virus, and wildtype HSV1 [McKrae] as a control for a series of experimental endpoints using four different mammalian cell lines that included rabbit skin cells, HeLa cells, mouse embryonic fibroblasts, and a neuronal cell line Neuro-2A. In contrast to the other three cell lines, HVEM protein expression was markedly reduced in v27 – 29-infected Neuro2a cells with no gD co-localization whereas Neuro-2A cells infected with v27 virus showed less HVEM and gD co-localization although gD protein levels remained unaffected. Additional studies showed that Neuro2A cells infected with a single or triple gD mutant showed significantly less expression of several HSV1 glycoproteins that included gB and gC as well as gD, host cell receptors, and various HVEM ligands. The authors conclude that amino acids Q27 – T29 rather than Q27 alone are essential to completely block gD binding to HVEM. This is a well written manuscript that summarizes the findings of a series of relatively straightforward in vitro studies that provide convincing outcomes. These studies represent a nice companion to recently published work by this research group investigating gD and HVEM binding using the two recombinant viruses v27 and v27 – v29 in a mouse model of HSV1 corneal infection and latency. Attention to a few minor issues might strengthen the manuscript, however. 1. The authors use the word “significantly” to describe results but without providing the necessary p values. See Line 134 and Line 160. Later in the manuscript, use of the word “significantly” is supported by p values (Lines 172 – 174). The authors might consider using the word “markedly” in place of “significantly” when p values are not provided. 2. Figures 4A and 4B show a comparison of the replication of wildtype virus, v27 virus, and v27 – 29 virus in Neuro2a cells. The authors state that at an moi = 1.0, the replication of v27 – 29 virus in Neuro2a cells was significantly less (p > 0.05) than that of v27 virus at 48 hours postinfection and further state that the replication of v27 and wildtype viruses was “13 times higher” than that of v27 – 29 [Line 180]. However, inspection of Figure 4B suggests the amounts of infectious virus at 12 and 24 hours postinfection are relatively the same. How do the authors explain the more pronounced difference at 48 hour postinfection when gD and HVEM binding are early events? Is this difference due to progeny virus infections of neighboring uninfected cells (moi = 1.0 PFU/cell). Would this difference be observed at an moi = 10? Secondly, the comparisons are being made on a log scale. Neuro2a cells infected with the v27 – 29 virus nonetheless produce high amounts of infectious virus approaching 1 X 10^6 PFU/ml. Would not the decrease expected to be much greater? While “statistically significant” and perhaps a marked trend in reduction, would the findings be biologically relevant in the clinical setting? Reviewer #3 Overall, the strength of this study demonstrated that a gD binding-site mutation, especially a triple aa mutation in gD, abolishes gD-HVEM binding or co-localization at the cell membrane. Although the gD binding-site mutation did not affect virus replication in non-neuronal cells (RS, HeLa cells, L929, MEF cells), it did interfere with virus replication in Neuro 2A cells. In addition, the gD mutation in v27 or V27-v29 leads to reduced transcription of viral glycoproteins gB, gC, and gD, host receptors (HVEM, Nectin-1, and 3OS-SH transcription, and HVEM ligands (LIGHT, LTz, CA160, and BTLA) compared to those infected with WT viruses. The major concerns with the manuscripts are that the effects of the gD mutation were assessed (quantified) mostly at the transcription level, not at the protein production level. The mechanisms by which the gD mutation affects viral replication, transcription of host receptors, and receptor ligands were not discussed in detail. There was a difference in HVME ligand transcription in response to V27 and V27-29 virus infection at 48h. The transcription of Ltα in V27 virus-infected cells was upregulated more than that in V27-29 virus-infected cells. Could this be the reason why the V27 viral titer was similar to the WT virus titer at 48hpi? The terms gD-HVEM binding and co-localization were used synonymously during testing. What are the different effects of gD-HVEM binding or co-localization on the cell membrane versus the binding within the cytoplasm? The following are specific issues to be addressed: 1. In Fig. 1A, the 3xmut-gD appears colocalized with HVEM in the cytoplasm of transfected cells, not on the cell membrane. How do you differentiate gD-HVEM binding or co-localization on the cell membrane or inside the cytoplasm? Is the gD trafficking to the membrane interfered by gD mutation? 2. The mutation in gD could be illustrated in an expanded subfigure with precise site mutations in Fig. 2. 3. In Fig. 5, there were still many green stains at 48hpi. How do you tell if those were viral GFP signals or HVEM staining in the infected cells? 4. In Fig. 6, there were significant differences in the transcription of gB, gC, and gD among WT, v27, and v27-29 infections in Neuro2A cells. Still, the final viral titer of the v27 infection was similar to that of the WT infection. Why is the final viral titer the same between WT and v27 virus infection in the neuro2A cells? Were translations of gB, gC, and gD affected at 48hpi between WT and V27 virus infection? 5. In Fig. 7, HVEM, Nectin-1, and 3OS-SH transcription at 48hpi were significantly lower in V27- and V27-29-virus-infected cells compared to WT virus-infected cells. However, it did not affect the virus titer at 48hpi in neuro2A cells infected with v27, except in cells infected with v27-29. Which of those receptors is compensating for the entry for V27 replication? 6. In Fig. 8, transcription of BTLA, LIGHT, Ltα, and CD160 was lower in the mutant virus infection compared to that in the WT virus infection. However, they all increased compared to the uninfected cells. The difference between v27 and v27-29 virus infection is not significant in the transcription of LIGHT and CD160. BTLA gene transcription had a slight increase in v27-v29 virus infection compared to v27-infected cells; on the other hand, Lymphotoxin-α had an increase in v27 infection compared to v27-29 infection. Therefore, the ligand response varies between v27 and v27-29. These differences were not highlighted in the results and discussion Minor comments: 1: In the materials and methods section, the description of co-expression of gD and HVEM in infected cells included a fixation step after antibody staining. Is this the same procedure used in co-transfection staining? 2. lines 305-307: only v27-29 virus infection in neuro2A cells had reduced viral titer at 48hpi. The statement should be revised. How do you explain the v27 virus infection with no significant viral titer change but with a significant gB, gC, and gD transcription reduction? 3. lines 309-311, "the graded reduction ----" needs to be revised? 4. line 326-329. BTLA, LIGHT, Ltα, and CD160 gene expression were all higher in infected cells than in mock-infected cells. They were lower in v27- and v27-29-infected cells than in WT virus-infected cells. This means there was no downregulation in those mutant virus-infected cells, but there was a lack of upregulation of HVEM ligand transcription. The discussion on those HVEM ligand expressions needs to be revised accordingly. Reviewer #4 Herpes simplex virus type 1 (HSV-1) glycoprotein D (gD) plays a major player of virus entry, in large part because it interacts with heparan, HVEM. Previous studies revealed that amino acid 27-29 completely blocked gD binding to HVEM. This was the rational for mutating amino acid 27 and a mutant virus aa 27-29. These mutants were in the McKrae strain of HSV-1, which is a highly virulent strain of HSV-1. These mutant viruses were used to compare viral replication, corneal disease, latency, reactivation form latency, and T cell exhaustion. This study revealed that the ability of gD to interact with HVEM is crucial for viral replication and reactivation from latency. In general, this is an interesting study because interfering gD-HVEM can be used to develop a vaccine or small molecules that blocks the binding of HVEM to gD. With that said, there are a few minor issues that need to be addressed. Minor issues: 1. The sentence on lines 27-29 needs to be revised because as is it indicates both mutant viruses were infected the same mice. “Mice infected with both mutant viruses had significantly lower eye disease, latency, and T cell exhaustion levels than observed in WT virus-infected mice.” 2. In Figure 1, the authors compare virus shedding when the eyes were scarified versus no scarification of wt MsKrae, the mutant containing only when position 27 was mutated (v27) or all 3 amino acids (v27-29) were mutated. As expected, both mutants had higher virus shedding when the eyes were scarified prior to infection. I was wondering if wt HSV-1 (McKrea) shed significantly higher than if not scarified? It looks like it does and the authors should consider stating whether the differences in virus shedding was significant or not. 3. Does HSV-2 gD contain the same amino acids at position of 27-29 of gD? 4. With respect to Figure 2, the authors should briefly explain how they measured corneal scarring and angiogenesis. 5. Figure 3 suggests there is no significant difference in LAT expression in TG regardless of scarification of the eyes of mice prior to no scarification. Can the authors comment on this? Journal Requirements: If the reviewer comments include a recommendation to cite specific previously published works, please review and evaluate these publications to determine whether they are relevant and should be cited. There is no requirement to cite these works unless the editor has indicated otherwise. 1) Please amend your detailed Financial Disclosure statement. This is published with the article. It must therefore be completed in full sentences and contain the exact wording you wish to be published. i) State what role the funders took in the study. If the funders had no role in your study, please state: "The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript." ii) If any authors received a salary from any of your funders, please state which authors and which funders.. If you did not receive any funding for this study, please simply state: u201cThe authors received no specific funding for this work.u201d Reviewers' Comments: [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] Figure resubmission: While revising your submission, we strongly recommend that you use PLOS’s NAAS tool (https://ngplosjournals.pagemajik.ai/artanalysis) to test your figure files. NAAS can convert your figure files to the TIFF file type and meet basic requirements (such as print size, resolution), or provide you with a report on issues that do not meet our requirements and that NAAS cannot fix. After uploading your figures to PLOS’s NAAS tool - https://ngplosjournals.pagemajik.ai/artanalysis, NAAS will process the files provided and display the results in the "Uploaded Files" section of the page as the processing is complete. If the uploaded figures meet our requirements (or NAAS is able to fix the files to meet our requirements), the figure will be marked as "fixed" above. If NAAS is unable to fix the files, a red "failed" label will appear above. When NAAS has confirmed that the figure files meet our requirements, please download the file via the download option, and include these NAAS processed figure files when submitting your revised manuscript. Reproducibility: To enhance the reproducibility of your results, we recommend that authors of applicable studies deposit laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. Additionally, PLOS ONE offers an option to publish peer-reviewed clinical study protocols. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols 6 Aug 2026 Submitted filename: Response (08-05-2026)PP.doc 20 Aug 2026 Dear Dr. Ghiasi, We are pleased to inform that your manuscript, "Complete Disruption of gD Binding to HVEM Alters Virus Replication and Host Receptor Homeostasis", has been editorially accepted for publication at PLOS Pathogens. Before your manuscript can be formally accepted and sent to production, you will need to complete our formatting changes, which you will receive by email within a week. Please note that your manuscript will not be scheduled for publication until you have made the required changes. IMPORTANT NOTES (1) Copyediting and Proofreading: The corresponding author will receive a typeset proof for review, to ensure errors have not been introduced during production. Please review the PDF proof of your manuscript carefully, as this is the last chance to correct any errors. Please note that major changes, or those which affect the scientific understanding of the work, will likely cause delays to the publication date of your manuscript. (2) Appropriate Figure Files: Please remove all name and figure # text from your figure files. Please also take this time to check that your figures are of high resolution, which will improve the readbility of your figures and help expedite your manuscript's publication. Please note that figures must have been originally created at 300dpi or higher. Do not manually increase the resolution of your files. For instructions on how to properly obtain high quality images, please review our Figure Guidelines, with examples at: http://journals.plos.org/plospathogens/s/figures. We encourage you to use PACE (http://pace.apexcovantage.com/), a figure-checking tool which helps authors ensure all figures meet PLOS requirements so that figures can publish in the highest quality. PACE is a digital diagnostic and conversion tool for figure files. It will provide information about any failed check(s) and, if able, will automatically convert the figure into an acceptable file that passes quality checks. To use PACE, you must first register as a user. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. (3) Striking Image: Please upload a striking still image to accompany your article if one is available (you can include a new image or an existing one from within your manuscript). Should your paper be accepted, this image will be considered for our monthly issue image and may also appear on our website to feature your article. Please upload this as a separate file, selecting "striking image" as the file type upon upload. Please also include a separate "Other" file with a caption, including credits and any potential copyright information. Please do not include the caption in the main article file. If your image is from someone other than yourself, please ensure that the artist has read and agreed to the terms and conditions of the Creative Commons Attribution License at http://journals.plos.org/plospathogens/s/content-license. Please note that PLOS cannot publish copyrighted images. (4) Press Release or Related Media: If you or your institution will be preparing press materials for this manuscript, please inform our press team in advance at plospathogens@plos.org as soon as possible. We ask that you contact us within one week to plan ahead of our fast Production schedule. If you need to know your paper's publication date for related media purposes, you must coordinate with our press team, and your manuscript will remain under a strict press embargo until the publication date and time. (5) Update your Profile Information: Now that your manuscript has been provisionally accepted, please log into Editorial Manager and update your profile, if needed. Go to http://www.editorialmanager.com/ppathogens, log in, and click on the "Update My Information" link at the top of the page. Please update your user information to ensure an efficient production and billing process. (6) LaTeX users only: Our staff will ask you to upload a TEX file in addition to the PDF before the paper can be sent to typesetting, so please carefully review our Latex Guidelines http://journals.plos.org/plospathogens/s/latex in the meantime. Thank you again for supporting Open Access publishing; we are looking forward to publishing your work in PLOS Pathogens. Best regards, Clinton Jones, PhD Academic Editor PLOS Pathogens Robert Kalejta Section Editor PLOS Pathogens Dominique Soldati-Favre Editor-in-Chief PLOS Pathogens *********************************************************** Reviewer's Responses to Questions Part I - Summary Please use this section to discuss strengths/weaknesses of study, novelty/significance, general execution and scholarship.

Reviewer #1: (No Response) Reviewer #2: The authors have responded to all concerns and questions raised during the initial review process. Reviewer #4: This is an important manuscript that provides novel insight into contributions of individual amino acid residues in gD to binding of the entry receptor HVEM and to viral and host gene expression. Available information demonstrates that the manuscript has been significantly modified and improved by following suggestions of reviewers #1 through #4. In my opinion the revised manuscript is sufficiently improved for publication. The results of this study are highly relevant as they potentially lead to novel therapeutic modalities that through targeting the gD Q27-T29 region, or downstream HVEM-dependent signaling, can selectively reduce HSV-1 reactivation without substantially compromising control of primary infection. -------------------- Part II – Major Issues: Key Experiments Required for Acceptance Please use this section to detail the key new experiments or modifications of existing experiments that should be absolutely required to validate study conclusions.

Generally, there should be no more than 3 such required experiments or major modifications for a "Major Revision" recommendation. If more than 3 experiments are necessary to validate the study conclusions, then you are encouraged to recommend "Reject".

Reviewer #1: (No Response) Reviewer #2: None Reviewer #4: No major issues: In my opinion the revised manuscript is sufficiently improved for publication. -------------------- Part III – Minor Issues: Editorial and Data Presentation Modifications Please use this section for editorial suggestions as well as relatively minor modifications of existing data that would enhance clarity.

Reviewer #1: (No Response) Reviewer #2: None Reviewer #4: No minor issues: In my opinion the revised manuscript is sufficiently improved for publication. -------------------- PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy. Reviewer #1: No Reviewer #2: No Reviewer #4: No Dear Dr. Ghiasi, We are delighted to inform you that your manuscript, "Complete Disruption of gD Binding to HVEM Alters Virus Replication and Host Receptor Homeostasis," has been formally accepted for publication in PLOS Pathogens. We have now passed your article onto the PLOS Production Department who will complete the rest of the pre-publication process. All authors will receive a confirmation email upon publication. Thank you again for supporting open-access publishing; we are looking forward to publishing your work in PLOS Pathogens. Best regards, Dominique Soldati-Favre Editor-in-Chief PLOS Pathogens